Advances in Therapy

, Volume 19, Issue 6, pp 266–274 | Cite as

Intravenous and local intra-arterial tissue-plasminogen activator in a rabbit model of acute thromboembolic stroke: Angiographic comparison

  • Bulent Erdogan
  • Orhan Sen
  • Hakan Caner
  • Necdet Ceviker
  • Kemali Baykaner
  • Erhan Ilgit


The aim of early thrombolytic therapy in acute stroke is to obtain early recanalization of occluded cerebral arteries and prevent or reduce irreversible ischemic brain damage. In this study, Seldinger technique and digital subtraction angiography were used to verify thromboembolic occlusion of the common carotid artery by an autologous 12-hour-old thrombus in 28 rabbits. Thirty minutes after embolization, 2 mg/kg of recombinant tissue-plasminogen activator (rt-PA) was delivered intravenously by way of the femoral vein in group A (n = 8) and through a local intraarterial infusion in group B (n = 8). Twelve control animals received an equivalent volume of saline intravenously (group C, n = 6) or by local intra-arterial infusion (group D, n = 6). A comparison of posttreatment angiographs of the treatment groups and the control groups was used to demonstrate reperfusion induced by thrombolytic therapy. None of the control animals showed any evidence of recanalization. Both intravenously (group A) and intra-arterially (group B) treated animals achieved 100% recanalization, although the average time to recanalization was significantly longer in group A (P = .01; 123.7 vs 82.5 min). These results suggest that local intra-arterial administration of rt-PA within 30 minutes produces more rapid reperfusion compared with the intravenous route. Further studies and additional treatments are needed to widen the therapeutic window and decrease hemorrhagic side effects.


tissue-plasminogen activator thromboembolic stroke thrombolysis rabbits 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Yepes M, Sandkvist M, Wong MK, et al. Neuroserpin reduces cerebral infarct volume and protects neurons from ischemia-induced apoptosis.Blood. 2000;96:569–576.PubMedGoogle Scholar
  2. 2.
    Fisher M, Bogousslavsky J. Further evolution toward effective therapy for acute ischemic stroke.JAMA. 1998;279:1298–1303.PubMedCrossRefGoogle Scholar
  3. 3.
    Toomey JR, Valocik RE, Koster PF, et al. Inhibition of factor IX (a) is protective in a rat model of thromboembolic stroke.Stroke. 2002;33:578–585.PubMedCrossRefGoogle Scholar
  4. 4.
    Adams RD, Victor M. Cerebrovascular diseases. In:Principles of Neurology. New York: McGraw-Hill; 1993:669–748.Google Scholar
  5. 5.
    The National Institute of Neurological Disorders and Stroke rt-PA Study Group. Tissue plasminogen activator for acute ischemic stroke.N Engl J Med. 1995;333:1581–1587.CrossRefGoogle Scholar
  6. 6.
    Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study (ECASS).JAMA. 1995;274:1017–1025.PubMedCrossRefGoogle Scholar
  7. 7.
    Haefelin CN, Brinker G, Pillekamp UU, Hossmann KA, Hoehn M. Prediction of hemorrhagic transformation after thrombolytic therapy of clot embolism.Stroke. 2002;33:1392–1398.CrossRefGoogle Scholar
  8. 8.
    Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute stroke.JAMA. 1995;274:1017–1025.PubMedCrossRefGoogle Scholar
  9. 9.
    Clark WM, Wissman S, Albers GW, et al. Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset.JAMA. 1999;282:2019–2026.PubMedCrossRefGoogle Scholar
  10. 10.
    Clark WM, Albers GW, Madden KP, Hamilton S, for the Thrombolytic Therapy in Acute Ischemic Stroke Investigators. The rt-PA (alteplase) 0–6-hour acute stroke trial, part A (A0276g). Results of a double blind, placebo-controlled, multicenter study.Stroke. 2000;31:811–816.PubMedGoogle Scholar
  11. 11.
    Philips DA, Davis MA, Fisher M. Selective embolization and clot dissolution with tPA in the internal carotid artery circulation of the rabbit.AJNR. 1988;9:899–902.Google Scholar
  12. 12.
    Hamilton MG, Lee JS, Cummings PJ, Zabramski JM. A comparison of intra-arterial and intravenous tissue type plasminogen activator on autologous emboli in the cerebral circulation of rabbits.Stroke. 1994;25:651–655.PubMedGoogle Scholar
  13. 13.
    Russell D, Madden KP, Clark WM, Zivin JA. Tissue plasminogen activator cerebrovascular thrombolysis in rabbits is dependent on the rate and route of administration.Stroke. 1992;23: 388–393.PubMedGoogle Scholar
  14. 14.
    Zeumer H, Freitag HJ, Knospe V. Intravascular thrombolysis in central nervous system cerebrovascular disease.Neuroimag Clin North Am. 1992;2:359–369.Google Scholar
  15. 15.
    Morgenstern LB, Staub L, Chan W, et al. Improving delivery of acute stroke therapy. The TLL Temple Foundation Stroke Project.Stroke. 2002;33:160–166.PubMedCrossRefGoogle Scholar
  16. 16.
    Furlan A, Higashida R, Wechsler L, et al. Intra-arterial prourokinase for acute ischemic stroke: the PROACT II study: a randomized clinical trial.JAMA. 1999;282:2003–2011.PubMedCrossRefGoogle Scholar
  17. 17.
    Gönner F, Remonda L, Mattle H, et al. Local intra-arterial thrombolysis in acute ischemic stroke.Stroke. 1998;29:1894–1900.PubMedGoogle Scholar
  18. 18.
    Sasaki O, Takeuchi S, Koike T, Koizumi T, Tanaka R. Fibrinolytic therapy for acute embolic stroke: intravenous, intracarotid, and intra-arterial local approaches.Neurosurgery. 1995;36: 1309–1310.CrossRefGoogle Scholar
  19. 19.
    Theron J, Coskun O, Huet H, Oliveira G, Toulas P, Payelle G. Local intraarterial thrombolysis in the carotid territory.Intervent Neuroradiol. 1996;2:111–126.Google Scholar
  20. 20.
    Lapchak PA, Aaujo DM, Song D, Wei J, Purdy R, Zivin JA. Effects of the spin trap agent disodium-[(tert-butylimino) methyl] benzene-1,3-disulfonate N-oxide (generic NXY-059) on intracerebral hemorrhage in a rabbit large clot embolic stroke model. Combination studies with tissue plasminogen activator.Stroke. 2002;33:1665–1670.PubMedCrossRefGoogle Scholar
  21. 21.
    Lapchak PA, Chapman DF, Zivin JA. Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke.Stroke. 2000;31:3034–3040.PubMedGoogle Scholar
  22. 22.
    Sumii T, Lo EH. Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats.Stroke. 2002;33:831–836.PubMedCrossRefGoogle Scholar
  23. 23.
    Zhang Z, Zhang L, Yepes M, et al. Adjuvant treatment with neuroserpin increases the therapeutic window for tissue-type plasminogen activator administration in a rat model of embolic stroke.Circulation. 2002;106:740–745.PubMedGoogle Scholar

Copyright information

© Health Communications Inc 2002

Authors and Affiliations

  • Bulent Erdogan
    • 1
  • Orhan Sen
    • 1
  • Hakan Caner
    • 1
  • Necdet Ceviker
    • 2
  • Kemali Baykaner
    • 2
  • Erhan Ilgit
    • 3
  1. 1.Department of NeurosurgeryBaşkent University, Faculty of MedicineAdana-AnkaraTurkey
  2. 2.Department of NeurosurgeryGazi University, Faculty of MedicineAnkaraTurkey
  3. 3.Department of RadiologyGazi University, Faculty of MedicineAnkaraTurkey

Personalised recommendations